Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
*On [[microscopic]] [[histopathological]] analysis, [[carotid body]] [[tumor]] composed of: | *On [[microscopic]] [[histopathological]] analysis, [[carotid body]] [[tumor]] composed of: | ||
**The chief or [[paraganglionic]] cells composing the predominant part of the [[tumor]] and contain [[eosinophilic]] granular materials and oval or round nuclei.<ref name="PatetsiosGable2002">{{cite journal|last1=Patetsios|first1=Peter|last2=Gable|first2=Dennis R.|last3=Garrett|first3=Wilson V.|last4=Lamont|first4=Jeffrey P.|last5=Kuhn|first5=Joseph A.|last6=Shutze|first6=William P.|last7=Kourlis|first7=Harry|last8=Grimsley|first8=Bradley|last9=Pearl|first9=Gregory J.|last10=Smith|first10=Bertram L.|last11=Talkington|first11=C.M.|last12=Thompson|first12=Jesse E.|title=Management of Carotid Body Paragangliomas and Review of a 30-year Experience|journal=Annals of Vascular Surgery|volume=16|issue=3|year=2002|pages=331–338|issn=08905096|doi=10.1007/s10016-001-0106-8}}</ref> | **The chief or [[paraganglionic]] cells composing the predominant part of the [[tumor]] and contain [[eosinophilic]] granular materials and oval or round nuclei.<ref name="PatetsiosGable2002">{{cite journal|last1=Patetsios|first1=Peter|last2=Gable|first2=Dennis R.|last3=Garrett|first3=Wilson V.|last4=Lamont|first4=Jeffrey P.|last5=Kuhn|first5=Joseph A.|last6=Shutze|first6=William P.|last7=Kourlis|first7=Harry|last8=Grimsley|first8=Bradley|last9=Pearl|first9=Gregory J.|last10=Smith|first10=Bertram L.|last11=Talkington|first11=C.M.|last12=Thompson|first12=Jesse E.|title=Management of Carotid Body Paragangliomas and Review of a 30-year Experience|journal=Annals of Vascular Surgery|volume=16|issue=3|year=2002|pages=331–338|issn=08905096|doi=10.1007/s10016-001-0106-8}}</ref> | ||
| Line 20: | Line 15: | ||
**Increased [[mitotic]] activity | **Increased [[mitotic]] activity | ||
**Atypical [[mitotic]] figures | **Atypical [[mitotic]] figures | ||
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | {| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|''' | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|''' Features on Gross Pathology'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|''' | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Image'''}} | ||
|- | |- | ||
| | |Characteristic findings of [[carotid body]] [[tumor]], include:<ref name="WienekeSmith2009">{{cite journal|last1=Wieneke|first1=Jacqueline A.|last2=Smith|first2=Alice|title=Paraganglioma: Carotid Body Tumor|journal=Head and Neck Pathology|volume=3|issue=4|year=2009|pages=303–306|issn=1936-055X|doi=10.1007/s12105-009-0130-5}}</ref> | ||
**Well-circumscribed with psudocapsule | |||
* | **The size of the [[tumor]] varies greatly and it may be as large as 10 cm | ||
* [[ | **The cutting surface is solid with a smooth, rubbery texture|| | ||
|[[File:Carotid body tumor.jpg|thumb|300px|Contributed by Paweł Kuźniar in wikimedia.commons]] | |||
|- | |- | ||
Revision as of 18:33, 16 April 2019
- On microscopic histopathological analysis, carotid body tumor composed of:
- The chief or paraganglionic cells composing the predominant part of the tumor and contain eosinophilic granular materials and oval or round nuclei.[1]
- The supporting or sustentacular cells responsible for the chemoreceptor activity of the carotid body
- The characteristic finding of this tumor is:
- Chief cells Arranged in distinctive pattern called cell balls (zellballen)
- Separated by fibrovascular stroma and surrounded by sustentacular cells
- The cytoplasm is pale and diffuse with occasional presence of the eosinophilic granules.[2]
- The nuclei are round to spindle shape.
- The tumor is highly vascular.
- Although there is no well-accepted histologic criteria for the diagnosis of malignant tumors, worrisome histologic features include:[3]
| Features on Gross Pathology | Image |
Characteristic findings of carotid body tumor, include:[3]
|
 |
| Patient with carotid body tumor | |||||||||||||||||||||||||||||||||||
| History, Physical examination, and evaluation of cnotralateral side | |||||||||||||||||||||||||||||||||||
| Patients with age < 50 years Patients with multiple paraganglioma Patients with a positive family history | The rest of the patients | ||||||||||||||||||||||||||||||||||
| SDHD genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHD mutation | Absence of SDHD mutation | ||||||||||||||||||||||||||||||||||
| SDHC and SDHB genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHC/B mutation | Absence of SDHC/B mutation | ||||||||||||||||||||||||||||||||||
| All the relatives should be evaluated for the presence of paragnaglioma | |||||||||||||||||||||||||||||||||||
| whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas | |||||||||||||||||||||||||||||||||||
| Presence of other paraganglioma | Absence of other paraganglioma | ||||||||||||||||||||||||||||||||||
| 24-hour urine catecholamines and MRI for biochemical screening | surveillance screening every 5 years | ||||||||||||||||||||||||||||||||||
- ↑ Patetsios, Peter; Gable, Dennis R.; Garrett, Wilson V.; Lamont, Jeffrey P.; Kuhn, Joseph A.; Shutze, William P.; Kourlis, Harry; Grimsley, Bradley; Pearl, Gregory J.; Smith, Bertram L.; Talkington, C.M.; Thompson, Jesse E. (2002). "Management of Carotid Body Paragangliomas and Review of a 30-year Experience". Annals of Vascular Surgery. 16 (3): 331–338. doi:10.1007/s10016-001-0106-8. ISSN 0890-5096.
- ↑ Bibbo, Marluce (2008). Comprehensive cytopathology. Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4160-4208-2.
- ↑ 3.0 3.1 Wieneke, Jacqueline A.; Smith, Alice (2009). "Paraganglioma: Carotid Body Tumor". Head and Neck Pathology. 3 (4): 303–306. doi:10.1007/s12105-009-0130-5. ISSN 1936-055X.